FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065402302> ?p ?o ?g. }

• W2065402302 endingPage "751" @default.
• W2065402302 startingPage "745" @default.
• W2065402302 abstract "The purpose of this study was to determine the feasibility of acquiring in vivo proton magnetic resonance spectroscopy of ovarian lesions at a magnetic field strength of 3 Tesla (T). The goal was to provide potentially diagnostic biochemical information that may aid in the characterization of ovarian neoplasms detected during clinical magnetic resonance imaging scanning.Fourteen patients referred to 2 gynecologic oncologic surgeons were examined in a whole-body 3.0 T clinical scanner using an 8-element phased-array surface coil. Single voxel spectroscopy (SVS) was undertaken after identification of lesions on T1-weighted and T2-weighted imaging. SVS was performed using the point resolved spectroscopy (PRESS) localization technique using a echo time (TE) of 135 milliseconds and repetition time (TR) of 2000 milliseconds and with 192 signal averages. Resonance integrals for the prominent signals from choline-containing compounds and creatine (Cr) were studied and presence of other prominent spectroscopic signals reported. Each SVS acquisition was performed in less than 8 minutes. Magnetic resonance spectral findings were correlated with the detailed pathology reports obtained after resection of each tumor.Pathology revealed 7 patients with malignant surface epithelial-stromal tumors, 3 patients with germ cell tumors, 3 patients with benign serous cystadenomas, and 1 patient with a non-neoplastic endometrioma. Spectroscopic data were acquired from 16 voxels in 14 patients. Resonances attributable to choline-containing compounds and Cr were recorded in all malignant tumors and some of the benign tumors. When detected, a choline/Cr integral ratio of greater than 3 was found to indicate that a tumor was malignant in nature, whereas a choline/Cr integral ratio less than 1.5 was found to indicate that a tumor was benign in nature. There was 1 exception, a 13-cm serous cystadenofibroma, where the choline/Cr integral ratio was 3.13. Several other prominent metabolites were recorded including lactate, lipid, and an as yet unassigned resonance (possibly N-acetylaspartate or sialic acid) at 2.07 ppm.Spectroscopy of ovarian masses can be recorded at 3.0 T with acceptable spectral quality and good signal-to-noise ratio. There are stringent technical considerations to be considered in obtaining good spectral quality. Further experience with a larger and more biologically variable range of tumors needs to be undertaken to determine the final clinical utility of this technique, but initial results from this small cohort are promising." @default.
• W2065402302 created "2016-06-24" @default.
• W2065402302 creator A5016216989 @default.
• W2065402302 creator A5028340687 @default.
• W2065402302 creator A5030851910 @default.
• W2065402302 creator A5042948256 @default.
• W2065402302 creator A5049964188 @default.
• W2065402302 creator A5077922970 @default.
• W2065402302 date "2008-10-01" @default.
• W2065402302 modified "2023-10-16" @default.
• W2065402302 title "Evaluation of Ovarian Tumors by Proton Magnetic Resonance Spectroscopy at Three Tesla" @default.
• W2065402302 cites W1963853697 @default.
• W2065402302 cites W1965072513 @default.
• W2065402302 cites W1967293578 @default.
• W2065402302 cites W1967874692 @default.
• W2065402302 cites W1971086254 @default.
• W2065402302 cites W1979533521 @default.
• W2065402302 cites W1980627022 @default.
• W2065402302 cites W1983064182 @default.
• W2065402302 cites W1986228486 @default.
• W2065402302 cites W1991413275 @default.
• W2065402302 cites W1996457684 @default.
• W2065402302 cites W1998061827 @default.
• W2065402302 cites W2013237043 @default.
• W2065402302 cites W2013522256 @default.
• W2065402302 cites W2015984331 @default.
• W2065402302 cites W2018218670 @default.
• W2065402302 cites W2027138920 @default.
• W2065402302 cites W2049196436 @default.
• W2065402302 cites W2055838114 @default.
• W2065402302 cites W2058027749 @default.
• W2065402302 cites W2063878915 @default.
• W2065402302 cites W2079872643 @default.
• W2065402302 cites W2080347147 @default.
• W2065402302 cites W2090871846 @default.
• W2065402302 cites W2093110246 @default.
• W2065402302 cites W2094790663 @default.
• W2065402302 cites W2101397252 @default.
• W2065402302 cites W2106173242 @default.
• W2065402302 cites W2111388536 @default.
• W2065402302 cites W2116309666 @default.
• W2065402302 cites W2121524318 @default.
• W2065402302 cites W2131597845 @default.
• W2065402302 cites W2140264773 @default.
• W2065402302 cites W2140472853 @default.
• W2065402302 cites W2144808290 @default.
• W2065402302 cites W2147428872 @default.
• W2065402302 cites W2171079076 @default.
• W2065402302 cites W2886052704 @default.
• W2065402302 cites W4239461267 @default.
• W2065402302 cites W4249955435 @default.
• W2065402302 doi "https://doi.org/10.1097/rli.0b013e31817e9104" @default.
• W2065402302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18791417" @default.
• W2065402302 hasPublicationYear "2008" @default.
• W2065402302 type Work @default.
• W2065402302 sameAs 2065402302 @default.
• W2065402302 citedByCount "47" @default.
• W2065402302 countsByYear W20654023022012 @default.
• W2065402302 countsByYear W20654023022013 @default.
• W2065402302 countsByYear W20654023022015 @default.
• W2065402302 countsByYear W20654023022016 @default.
• W2065402302 countsByYear W20654023022017 @default.
• W2065402302 countsByYear W20654023022018 @default.
• W2065402302 countsByYear W20654023022019 @default.
• W2065402302 countsByYear W20654023022020 @default.
• W2065402302 countsByYear W20654023022021 @default.
• W2065402302 countsByYear W20654023022022 @default.
• W2065402302 crossrefType "journal-article" @default.
• W2065402302 hasAuthorship W2065402302A5016216989 @default.
• W2065402302 hasAuthorship W2065402302A5028340687 @default.
• W2065402302 hasAuthorship W2065402302A5030851910 @default.
• W2065402302 hasAuthorship W2065402302A5042948256 @default.
• W2065402302 hasAuthorship W2065402302A5049964188 @default.
• W2065402302 hasAuthorship W2065402302A5077922970 @default.
• W2065402302 hasConcept C103191249 @default.
• W2065402302 hasConcept C118552586 @default.
• W2065402302 hasConcept C121332964 @default.
• W2065402302 hasConcept C126322002 @default.
• W2065402302 hasConcept C126838900 @default.
• W2065402302 hasConcept C142724271 @default.
• W2065402302 hasConcept C143409427 @default.
• W2065402302 hasConcept C150173356 @default.
• W2065402302 hasConcept C16568411 @default.
• W2065402302 hasConcept C2776694085 @default.
• W2065402302 hasConcept C2776938808 @default.
• W2065402302 hasConcept C2779889316 @default.
• W2065402302 hasConcept C2779896295 @default.
• W2065402302 hasConcept C2781123555 @default.
• W2065402302 hasConcept C2908988626 @default.
• W2065402302 hasConcept C2988005100 @default.
• W2065402302 hasConcept C2989005 @default.
• W2065402302 hasConcept C46141821 @default.
• W2065402302 hasConcept C71924100 @default.
• W2065402302 hasConceptScore W2065402302C103191249 @default.
• W2065402302 hasConceptScore W2065402302C118552586 @default.
• W2065402302 hasConceptScore W2065402302C121332964 @default.
• W2065402302 hasConceptScore W2065402302C126322002 @default.
• W2065402302 hasConceptScore W2065402302C126838900 @default.

• next